Nurexone Biologic Inc
F:J90
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (5.1), the stock would be worth €-0.42 (210% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.6 | €0.38 |
0%
|
| Industry Average | 5.1 | €-0.42 |
-210%
|
| Country Average | 10.2 | €-0.84 |
-320%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Nurexone Biologic Inc
F:J90
|
25.5m EUR | -4.6 | -4.6 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
217B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 417.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
95.6B ZAR | 14 | 10.2 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
33.9B CHF | 0 | 0 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
40.4B USD | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
29.3B EUR | 29.9 | 164.6 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
29.8B USD | -3 580.1 | -2 733.7 | |
| US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
28B USD | 0 | 0 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
27.9B ZAR | 16.8 | 6.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
